Lipids in Health and Disease

Table 3 Follow-up lipid and lipoprotein cholesterol levels after 4 weeks on PCSK9 inhibitor therapy, mean ± SD [median]

From: Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

	Lipids mg/dl	Pre-treatment	After 4 weeks on PCSK9 inhibitor	Change (mg/dl)	% change	p (paired Wilcoxon test)
Of 103 patients, 94 at 4 weeks follow up	TC	251 ± 59 [249]	158 ± 49 [159]	−93 ± 54 [−82]	−36 ± 18 % [−36 %]	<.0001
	TG	163 ± 85 [140]	125 ± 48 [119]	−38 ± 70 [−24]	−16 ± 30 % [−18 %]	<.0001
	HDLC	54 ± 16 [54]	57 ± 17 [55]	+2 ± 9 [+2]	+6 ± 15 % [+4 %]	.0005
	LDLC	166 ± 55 [152]	77 ± 43 [76]	−89 ± 50 [−79]	−52 ± 23 % [−54 %]	<.0001
Of 61 patients with CVD pre study, 56 at 4 weeks follow up	TC	235 ± 56 [230]	148 ± 46 [146]	−88 ± 52 [−80]	−36 ± 19 % [−37 %]	<.0001
	TG	163 ± 97 [138]	118 ± 45 [115]	−44 ± 79 [−31]	−18 ± 29 % [−20 %]	<.0001
	HDLC	54 ± 18 [51]	57 ± 19 [53]	+3 ± 10 [+2]	+7 ± 17 % [+5 %]	.002
	LDLC	151 ± 51 [141]	68 ± 39 [60]	−83 ± 46 [−79]	−54 ± 24 % [−57 %]	<.0001

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com